Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Eugene Redmond

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cell Transplantation|April 4, 2015
A potential compensatory role for endogenous striatal tyrosine hydroxylase-positive neurons in a nonhuman primate model of Parkinson's diseaseAndrew N Bubak, D Eugene Redmond, John D Elsworth, et al.
Brain Research. Developmental Brain Research|December 4, 2003
Spatiotemporal patterns of gene expression during fetal monkey brain developmentD Eugene Redmond, Ji-Liang Zhao, Jeffry D Randall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 17, 2009
Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brainEleni A Markakis, Kenneth P Vives, Jeremy Bober, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 6, 2013
Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's modelD Eugene Redmond, Caleb R S McEntire, Joseph P Kingsbery, et al.
Cell Transplantation|April 4, 2015
Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's diseaseRodolfo Gonzalez, Ibon Garitaonandia, Andrew Crain, et al.
Current Neuropharmacology|June 2, 2012
Functional multipotency of stem cells: a conceptual review of neurotrophic factor-based evidence and its role in translational researchYang D Teng, Dou Yu, Alexander E Ropper, et al.
Human Gene Therapy|January 5, 2006
Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primatesNeil R Hackett, D Eugene Redmond, Dolan Sondhi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological NanoparticlesWuping Li, Aravind Asokan, Zhijian Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2008
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticlesWuping Li, Aravind Asokan, Zhijian Wu, et al.
Endocrinology|June 18, 2003
Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's diseaseTamas L Horvath, Sabrina Diano, Csaba Leranth, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cell Transplantation|April 4, 2015
A potential compensatory role for endogenous striatal tyrosine hydroxylase-positive neurons in a nonhuman primate model of Parkinson's diseaseAndrew N Bubak, D Eugene Redmond, John D Elsworth, et al.
Brain Research. Developmental Brain Research|December 4, 2003
Spatiotemporal patterns of gene expression during fetal monkey brain developmentD Eugene Redmond, Ji-Liang Zhao, Jeffry D Randall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 17, 2009
Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brainEleni A Markakis, Kenneth P Vives, Jeremy Bober, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 6, 2013
Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's modelD Eugene Redmond, Caleb R S McEntire, Joseph P Kingsbery, et al.
Cell Transplantation|April 4, 2015
Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's diseaseRodolfo Gonzalez, Ibon Garitaonandia, Andrew Crain, et al.
Current Neuropharmacology|June 2, 2012
Functional multipotency of stem cells: a conceptual review of neurotrophic factor-based evidence and its role in translational researchYang D Teng, Dou Yu, Alexander E Ropper, et al.
Human Gene Therapy|January 5, 2006
Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primatesNeil R Hackett, D Eugene Redmond, Dolan Sondhi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological NanoparticlesWuping Li, Aravind Asokan, Zhijian Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2008
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticlesWuping Li, Aravind Asokan, Zhijian Wu, et al.
Endocrinology|June 18, 2003
Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's diseaseTamas L Horvath, Sabrina Diano, Csaba Leranth, et al.
Pageof 5